NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Provides Review of Successful 2024 Advancing the Field of Breast Cancer Treatment
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Sectors of Businessย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ January 9, 2025 โ Agendiaยฎ, Inc. today ย provided a topline review of the companyโs key Read More
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrintยฎ as the only commercially available genomic signature that may identify patient subgroups with resistance to CDK4/6 inhibition New real world evidence from FLEX adds to the growing body of Read More
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrintยฎ in predicting chemotherapy benefit for distant recurrence free interval among patients with HR+HER2-early-stage breast cancerย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 11, 2024 โ Read More
Newsroom
News, Stories & Breast Cancer Blog
Laura J. van โt Veer, PhD, Honored With 2024 William L. McGuire Memorial Lecture Award at SABCS 2024
SAN ANTONIO โ Laura J. van โt Veer, PhD, will receive the William L. McGuire Memorial Lecture Award during the San Antonio Breast Cancer Symposium (SABCS) 2024, to be held December 10-13 at the Read More
Gene Assay for MammaPrint May Predict Responses to Extended Letrozole in Low-Risk Breast Cancer Subsets
By Roman Fabbricatore | August 30, 2024 A gene assay was predictive of response to extended letrozole therapy, identifying a subset of patients with low-risk breast cancer with improved outcomes. The 70-Gene MammaPrint (MP) Read More
Personalized Breast Cancer Treatment Offered by Texas Breast Center Utilizes Agendia
Texas Breast Center, led by renowned breast surgeon Dr. Valerie Gorman, is pleased to announce the use of Agendia, a global leader in genomic testing. This collaboration aims to provide patients with the most Read More
Hormonal Therapy Story: How Laura-Lynn Renner Made an Informed Choice
By Kris Conner | August 7, 2024 How the diagnostic test MammaPrint empowered Laura-Lynn to find answers and advocate to improve the quality of her life. In the summer of 2020, Laura-Lynn Renner, a Read More
What Is Chemotherapy?
Along with surgery or radiation therapy, chemotherapy is one of the most common ways to treat cancer. Chemotherapy treatment is designed to destroy cancer cells; it can be used for primary cancer (cancer that Read More
Anthracycline Plus Chemo Associated With Improved RFS in MP High-2โRisk, HR+/HER2โ Early Breast Cancer
By Ryan Scottย June 1, 2024 Key Takeaways Patients with MammaPrint high-2, BluePrint Luminal B, HR-positive, HER2-negative early breast cancer had better 3-year RFS with anthracycline plus a taxane and cyclophosphamide. Luminal MP high-1โrisk Read More
Improved RFS Seen with Anthracycline Plus Chemo in MP High-2โRisk, HR+/HER2โ Early Breast Cancer
By Ryan Scottย June 1, 2024 A lower risk of disease recurrence was seen when combining anthracycline and chemotherapy to treat certain patients with breast cancer. Anthracycline plus a taxane and cyclophosphamide was linked to Read More
